

The Incidence of Hepatocellular Carcinoma in Iraq Population

Professor Dr. Ali Abid Saadoon

M.B.Ch.B, MSc, Ph D Community Physician, Dean College of Medicine / University of Warith Al-Anbiayaa

Email:ali.abid.s@utq.edu.iq

alisaadoon755@yahoo.com

Mudhafar Razzaq Hayyawi, MBChB, JICMS & CABMS in General Surgery, D. S., Al-Nasiriyah Teaching Hospital / Thi Qar Health Directorate.

Maitham Fadhil Hassan, MBChB, FICMS& CABMS in General Surgery, Suq Al-Shuyukh /Thi Qar Health Directorate.

Yakeen Kassim Abdul Hassan, Medical Student

Introduction of Hepatocellular carcinoma (HCC)

It is the most common type of primary liver cancer in adults and Is currently the most common cause of death in people with cirrhosis.[1] HCC Is the third leading cause of cancer-related deaths worldwide. Hepatocellular carcinoma (HCC) is a major health problem worldwide, due to its high incidence (approximately 600000 new cases in 2000), and high rates of mortality [1]. The identification that chronic liver disease is the process relevant risk factor for this tumour, has made surveillance campaigns aimed at early detection of HCC possible and surveillance is now universally recognised to be the practical approach for improving treatment of HCCpatients . The few cases (less than 5%) of HCC that do not develop on the background of chronic liver disease present late and usually have poor chances of cure.

Background

The development of HCC is a major global health problem , It's incidence has increased world wide

And nowadays it constitute the 5th most frequent cancer representing around 5% of all cancers, and

Estimated to rank 4th in terms of mortality of cancers incidence world wide , itaccounts for

80 –90%

Of all primary liver tumors . The Etiology of this tumor is multifactorial , certain viral, environmental

& hereditary causes of cirrhosis have a strong correlation with HCC . HCC is a highly malignant

Tumor with poor prognosis.

Risk factors

Since HCC mostly occurs in people with cirrhosis of the liver, risk factors generally include factors which cause chronic liver disease that may lead to cirrhosis. Still, certain risk factors are more highly associated with HCC than others. For example, while heavy alcohol consumption is estimated to cause 60–70% of cirrhosis, the vast majority of HCC occurs in cirrhosis attributed to viral hepatitis (although there may be overlap). Recognized risk factors include:

- Chronic viral hepatitis (estimated cause of 80% cases globally)
 - Chronic hepatitis B (about 50% cases)
 - Alcohol use disorder: the most common cause of cirrhosis
 - Aflatoxin
 - Iron overload state (hemochromatosis)
 - Pyrrolizidine alkaloids
- Metabolic:
 - Nonalcoholic steatohepatitis: up to 20% progress to cirrhosis
 - Nonalcoholic fatty liver disease
 - Type 2 diabetes (probably aided by obesity)
- Congenital disorders:
 - Alpha 1-antitrypsin deficiency
 - Wilson's disease (controversial; while some theorise the risk increases, case studies are rare and suggest the opposite where Wilson's disease actually may confer protection
 - Chronic hepatitis C (a Hemophilia, although statistically associated with higher risk of HCC,[15] this is due to coincident chronic viral hepatitis infection related to repeated blood transfusions.

Epidemiology

HCC is more common among males with a male:female ratio of 2.4 in its worldwide distribution.[3] The most common age at presentation is usually between 30 and 50 years.[4] HCC is predominant in Asian countries including China, Mongolia, Southeast Asia, and Sub-Saharan Western and Eastern Africa. The prevalence of HCC in developed countries of the world is lower, except Japan, Italy, and France. In the US surveillance, epidemiology, and end results (SEER) database program, HCC accounts for 65% of all cases of liver cancers. The incidence rate of HCC has increased from 1.4/100,000 cases/year between 1976–1980 to 6.2/100,000 cases reported in 2011. There are almost two times higher incidence of HCC among dark-skinned males compared to light-skinned males; a similar trend is seen among females with two times higher incidence rate among dark-skinned when compared to light-skinned.[8] The 5-year survival trend has improved by >60% from 1975 to 2005.[5]

Diagnostic

Hepatocellular carcinoma (HCC) is responsible for a large proportion of cancer deaths worldwide. Deterioration at which time survival is measured in months. Long-term survival requires detection of small tumors, often present in asymptomatic individuals, which may be more amenable to invasive therapeutic options. Surveillance of high-risk individuals for HCC is commonly performed using the serum marker alpha-fetoprotein (AFP) often in combination with ultrasonography. Various other serologic markers are currently being tested to help improve surveillance accuracy. Diagnosis of HCC often requires more sophisticated imaging modalities such as CTscan and MRI, which have multiphasic contrast enhancement capabilities. Serum AFP used alone can be helpful if levels are markedly elevated, which occurs in fewer than half of cases at time of diagnosis. Confirmation by liver biopsy can be performed under circumstances when the diagnosis of HCC remains unclear.

HCC is frequently diagnosed after the development of clinical signs and symptoms of this serious disease.

Physical findings:

If the tumour is small and often without symptoms no physical signs may be found at all
Signs related to the chronic liver disease and/or underlying cirrhosis is seen in more advanced cases.

Palpable mass in the upper abdomen, or a hard, irregular liver surface
Tenderness in the upper right abdominal quadrant

Splenomegaly, ascites, jaundice (also symptoms of cirrhosis)
Hepatic arterial bruit (heard over the tumour)

Signs that should raise a suspicion of HCC in patients with previously compensated cirrhosis:

Rapid deterioration of liver function
New-onset (or refractory) ascites
Acute intra-abdominal bleeding
Increase jaundice

Weight loss and fever

New-onset encephalopathy
Variceal bleeding

Patients with late-stage HCC may present with: Right upper quadrant abdominal pain
Symptoms and signs of underlying cirrhosis
Weakness

Abdominal s
Nonspecific gastrointestinal symptoms
Jaundice

Loss of appetite
Weight loss
Anorexia
Laboratory findings:

Usually nonspecific
Signs of cirrhosis:

Thrombocytopenia
Hypoalbuminaemia
Hyperbilirubinaemia
Coagulopathy
Electrolyte disturbances

swelling

Liver enzymes abnormal, but nonspecific

Elevated alpha foetoprotein (AFP; requires definitions of levels and appropriate setting)

Prevention

Factors that have been consistently shown to promote the prevention of HCC among the general population and chronic liver disease patients include coffee consumption, aspirin use, and metformin use, with the highest evidence for coffee use (the risk of HCC reduced by 40% for any coffee consumption vs no consumption). Evidence from two population-based studies demonstrated that statin use was associated with a 39% lower risk of liver cancer, which was notable in HCC but not in intrahepatic bile duct carcinoma [6]. High-quality meta-analyses and systematic reviews have shown that HCC risk, even though not fully eliminated, is reduced up to 80% in patients with hepatitis C virus (HCV)-related cirrhosis who attain sustained viral response (SVR) after the use of direct-acting antivirals.

Nonetheless, among those who achieved SVR, HCC risk was still high in the presence of continued alcohol use, older age, infection with HCV genotype 3, and elevated hepatic fibrosis markers(7)

Aime of study

To detect the prevalence of hepatocellular carcinoma in the patient with liver disease and aim of this study was to provide an updated overview on clinicopathological features of this serious disease.

Justification

Because the liver is the important organ in the body so we need to care for and detect any complication in the liver and because hepatocellular carcinoma the most common type of cancer in the liver

Methodology

Type of study: It is diagnostic to assess hepatocellular carcinoma

- **Study Design :**

-Cross-sectional study used to evaluate hepatocellular carcinoma

- **Study pattern:**

Electronic questionnaire

Place & time of study done in Thi-Qar Governorate/Al- Nasiriya city in 2023/3/9

- **study population:** the population of Thi-Qar 2 million the study includes the patient in hospital age from 20 /70 year

Ethical consideration had been attained from the scientific Community Medicine / Department in College Medicine of Thi – Qar University and also written consent had been attained from the participants.

Definition of variable: HHc is complex diseases affected the liver 1

Statistical Analysis A Chi square was used to check for any significant differences between the mean values of two continuous variables. The level P

Epidemiology analysis. Prevalence of HCC among population = number of HHc patient / population

Table(1):

Case	Type	No. of Patients	%
History Of Chronic Liver Disease	Hepatitis	62	30%
	Alcoholic Liver Disease	31	15.12%
	Cirrhosis Of		
	Unknown Etiology	29	14.1%
	Jaundice	78	38.04%
	Smoker	60	29.26 %
	Disturbed Lipid profile	72	13.1%
	Decresed Weight	90	43.9%
	Total	205	

Table(2):

Gender	With HCC	Without HCC	Total
Female	9	104	113
Male	25	67	92
Total	34	171	

Table(3): Prevalance of HCC and alcohol drinking

Drinking Alcohol	One Time	(3-4)times	More 4	Without Drink
31	8	7	16	174

Table(4): Prevalence of HCC with liver cirrhosis

With Liver Cirrhosis	Without Liver Cirrhosis	Total
29 16.4	148 83.6	177

Table(5): Prevalence of HCC With Hepatitis

With Hepatitis	Without Hepatitis	Total
62. 30.2	143 69.8	205

Table(6): Prevalence of HCC with jaundice

With Jaundice	With Out Jaundice	Total
78	127	205

Table(7): Prevalance of HCC with smoking

No. of Smokers	No. of nonsmokers	Total
60	145	205

Table(8):

Age Groups	Male	Female
18	2	2
18/24	3	2
24/40	6	2
41/60	13	3
More than 60 years	10	2

Results:

Prevalence of HCC with hepatitis is 30% Prevalence of HCC With liver cirrhosis is 14.5%
Prevalence of HCC with alcohol is a 15.5 % Prevalence of HCC. With Jundic us 78%
Prevalence of HCC with Smoker is 60%

Male to female ratio is approximately (3:1), The mean age of (57.1) yr . more common
between ((41-60)) yrs old (28.25%) , . Increasing no. of patients

(16%) haven't such a history . Most of chronic liver diseases are due to previous history of
hepatitis

B- infection (41.6%) . High level of AFP (66.6%), all of them are of standard type of
HCC. Ascitic

Increase above 18 7%. 18/24 8.75%. 24_40 14%. 41-60 28.25

Above 60 21%

Fluid cytological study bloody (14%) & positive malignant cells (17.2%) . Liver biopsy
(82.7%) had

More common in smoker and liver cirrhosis

Chronic liver diseases, and (96.5%) moderate to poorly differentiated type of standard
HCC,(3.5%)

Fibrolamellar type .Outcome of treatment , Conservative (35%), Injection therapy(3.5 ,
Debulking (9%:-

Strength of Study:

- The strength of this study included the following: a large number of random
samples reached 204 random
- Samples during a short period (2month,), where there was enough time to collected
sample

Limitations:

- There are some obstacles that this study faced, including the difficulty of dealing well
- With some patients to fill out the questionnaire. Some patients are bothered by the large
number of
- Questions, but their number was less compared to the rest of the patients. Also, poor
teamwork to Complete this study.

Conclusions:

1. The main Etiological causes of HCC were History of chronic liver diseases and the main cause Past history of Hepatitis B. and Hepatitis C. viral Infection and liver cirrhosis of unknown Etiology.
2. The most common presenting symptoms Abdominal pain and abdominal swelling and theLeast one is Jaundice. And the most c

References:

- 1- Forner A, Llovet JM, Bruix J (March 2012). "Hepatocellular carcinoma".Lancet. 379 (9822): 1245–1255. Doi:10.1016/S0140-6736(11)61347-0. PMID 22353262. S2CID 24927898.
- 2- Global Cancer Observatory". Gco.iarc.fr. Retrieved 2021
- 3- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics,CA Cancer J Clin. 2005;55:74–108. [PubMed] [Google Scholar]
- 4- 4. Kumar V, Abbas AK, Fausto N, Robbins SL, Cotran RS. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia: Elsevier Saunders; [Google Altekruze SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from J Clin Oncol. 27:1485–91. [PMC free article] [PubMed] [Google Scholar]
- 5- Statin use and risk of liver cancer: evidence from two population-based studies. Tran KT, McMenamin ÚC, Coleman HG, et al. Int J Cancer. 2020;146:1250–1260. [PubMed] [Google Scholar] Scholar]
- 6- Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Hepatology. 2018;68:449–461. [PMC free article] [PubMed] [Google Scholar]
- 7- Van damme P. , Kane M. , Meheus A. : for the Viral hepatitis , prevention board integration of Hepatitis B vaccination into national Immunization programs BMJ. 1997;314:1033
- 8- Sherlock S. : Hepatic tumors in Disease of the Liver and biliary system 8th ed. , London Blackwell scientific , 1989:558.
- 9- Akriviadis EA. , liovet JM. , Efremidis SC. Et Al : HCC. Brit J. Surgery 1998;85: 1319 – 31 .I
- 10- Niederani C. , Fischer R. , Sonneberg A. et al : Survival and causes of death in cirrhotic and In non cirrhotic patients with primary Hemochromatosis N. Eng J. Med . 1995;313 : 1256 – 62 .

- 11- Purtillo DT. : chlonorchiasis and hepaticTumors. Geop. Med. 1976;28:21-27 .
- 12- Jay, H.S.: Internal Medicine, little Brown and Company Boston, Toronto, 6th ed . 1997:1804 .
- 13- Abou – shady – M . :Molecular aspects of HCC , department of visceral & Transplantation surgery , University of Bern . Inselspital switzerland . Swiss Surg. 1995;5 :102 – 6.
- 14- Zuhair Alkassir , Ziad M . Juredini : HCC. InIraq . J- Fac. Medicine Baghdad – 1986 ;28.
- 15- Green field, L.I. , Mutholland, M., Oldham, T.: Surgery scientific principles and practice . 2nd Ed. LippincottRaven,Philadelphia1996:490.
- 16- Flickinger JC . , Carr BI . , Lotz MT. : cancerOf the liver . In Devita Vt. , Hellman S., Rosenberg SA. , eds cancer : principles and Practice of oncology . 5th ed . Philadelphia : Lippincott – Raven , 1997:1087–97 .
- 17- Chalasani N ., Hollander JC sr., said A. et al :Screening for HCC in patients with advanced Cirrhosis . Am. J. Gastroenterology 1999;94: 2988 – 93 .
- 18- International Agency for Research on Cancer ,Hepatitis viruses , Lyon , France , In Agency Res. Cancer 1994 (IARC Mongr 59) .
- Sherman M. : Alphafeto protein : An obtituary J. Hepatol. 2001; 34 : 603

